Joint CORP

The Joint Corp. announced the results of its 2026 annual meeting of stockholders, including the election of seven directors and advisory approval of executive compensation.

The Joint Corp. has amended its credit agreement to waive a default and extend its maturity date, while also reporting a 13% revenue increase and a 34% rise in net income for Q1 2026.

The Joint Corp. has entered an agreement to sell 45 corporate-managed clinics in Southern California for $2.3 million, accelerating its transition to a pure-play franchisor model.

The Joint Corp. has entered into an agreement to sell 45 company-owned or managed clinics in Southern California to Elite Chiro Group for $2.3 million.

The Joint Corp. reported increased revenues and net income for Q4 and full year 2025, driven by refranchising efforts and operational improvements, despite a decline in system-wide and comp sales.

The Joint Corp. filed an amended 8-K to correct the summary of a letter agreement with Bandera Partners LLC and Jefferson Gramm regarding board nomination and share ownership.

The Joint Corp. reported a net income of $1.9 million for the nine months ended September 30, 2025, driven by its refranchising strategy, despite a decrease in comparable same-store sales.

The Joint Corp. reported a net income of $1.06 million for the first six months of 2025, a significant turnaround driven by its refranchising strategy and growth in its franchise operations.

The Joint Corp. filed an amended quarterly report, restating Q1 2025 financial statements due to material errors in asset valuation and disclosing a material weakness in internal controls.

The Joint Corp. announces its Q1 2025 financial results, highlighting a strategic shift towards franchise-focused expansion and the ongoing refranchising of company-owned clinics.

The Joint Corp. announced its Q3 2024 financial results, highlighting a strategic move to re-franchise the majority of its company-owned clinics.

The Joint Corp. reported a net loss for the second quarter of 2024, while continuing its strategic shift towards re-franchising company-owned clinics.

The Joint Corp. announced a restatement of its 2024 annual and Q1 2025 interim financial statements due to a material error in asset valuation for discontinued operations, alongside identifying a material weakness in internal controls.

The Joint Corp. announces its fiscal year 2024 results, highlighting a shift towards a pure-play franchisor model and continued system-wide sales growth.

The Joint Corp. reports a 12% increase in system-wide sales to $488 million and a 4% increase in comparable store sales for 2023, while shifting focus to franchise development.

Chief Financial Officer Scott Justin Bowman surrendered 1,392 shares of The Joint Corp to satisfy tax liabilities following the vesting of restricted stock.

Director Milind Pant reported the acquisition of 5,714 restricted shares of JOINT Corp common stock on May 20, 2026.

Director Christopher M. Grandpre acquired 5,714 restricted shares of The Joint Corp. as part of an equity grant.

The Joint Corp. director Ronald V. DaVella was granted 5,714 restricted shares of common stock vesting in May 2027.

10% owner Charles E. Jobson acquired 148,051 shares of The Joint Corp (JYNT) in open market transactions.

Reporting person Charles E. Jobson acquired 509 shares of The Joint Corp (JYNT) at a price of $8.58 per share.

The Joint Corp. announces a return to profitability in 2025 with $2.9 million net income and 13.9% Adjusted EBITDA growth, driven by refranchising efforts and strategic initiatives.

The Joint Corp. has filed a definitive proxy statement with the SEC.

The Joint Corp.'s proxy statement outlines the company's strategic initiatives to become a world-class franchisor, improve profitability, and drive growth, while also detailing executive compensation and corporate governance matters.

The Joint Corp. issues a supplement to its proxy statement addressing concerns raised by Institutional Shareholder Services (ISS) regarding the approval of the 2024 Incentive Stock Plan and clarifying director attendance at board meetings.

The Joint Corp outlines its strategic vision to champion chiropractic care through refranchising, brand elevation, and a new incentive stock plan.

Bandera Partners LLC and its principals now beneficially own 27.9% of JOINT Corp's common stock, an increase in percentage driven by a decrease in the total outstanding shares, not new transactions.

Bandera Partners LLC, holding 26.5% of JOINT Corp shares, has reached an agreement for Jefferson Gramm to be nominated to the company's Board of Directors.

Bandera Partners, holding a 26.3% stake in JOINT Corp, has entered into an Amended Nomination and Standstill Agreement, securing a board nomination for Jefferson Gramm and agreeing to certain voting and acquisition restrictions.

Charles E. Jobson has filed a Schedule 13G, reporting beneficial ownership of 1,793,854 shares, representing 12.5% of JOINT Corp's common stock.

Individual investor Charles E. Jobson has filed an amendment reporting an 11.4% beneficial ownership stake in The Joint Corp.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in The Joint Corp. following an internal realignment.

Skylands Capital, LLC has reported a 6.0% beneficial ownership stake in The Joint Corp., holding 890,045 shares of common stock as of December 31, 2025.

Charles E. Jobson has reported an increased beneficial ownership of 1,549,105 common shares, representing 10.1% of JOINT Corp.

Charles E. Jobson has increased his beneficial ownership in JOINT Corp to 7.0% of the common stock, holding 1,075,994 shares.